HOW TOPICAL BETA-BLOCKER DID WONDER IN THE MANAGEMENT OF RESIDUAL HEMANGIOMA AFTER PROPRANOLOL THERAPY
- Resource Type
- Authors
- Rakesh Kumar; Vinit Kumar Thakur; Zaheer Hasan; Rupesh Keshri; Digamber Chaubey
- Source
- INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH. :44-46
- Subject
- business.industry
medicine.drug_class
Propranolol
medicine.disease
eye diseases
body regions
Hemangioma
030207 dermatology & venereal diseases
03 medical and health sciences
0302 clinical medicine
030220 oncology & carcinogenesis
Anesthesia
medicine
sense organs
business
Beta blocker
medicine.drug
- Language
Background: To determine the role of topical β- blocker in the management of residual hemangioma after propranolol therapy. Method: A retrospective study of all pediatric patients presenting with hemangioma from April 2014 to March 2019 was performed. Topical timolol gel was applied over the residual hemangioma which persisted even after one year of propranolol therapy. Result: Out of 68 patients included in this study 45 (70.3%), patients had complete resolution by one year using the treatment with propranolol. In 14 patients (21.8%) had residual lesion even after 1 year of treatment, upon which we applied topical timolol 0.5% gel for further 4 to 6 months. (Mean 5.35 months). At the end of the treatment, hemangioma was almost resolved. Conclusion: Timolol is a safer alternative to propranolol for residual hemangioma as a sequential treatment. It augments the regression of residual hemangioma with minimal side effects.